Targeting MYCN in neuroblastoma by BET bromodomain inhibition.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Discovery

• Publication date

  2013-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/2159-8290.CD-12-0418PMID 23430699PMCID PMC3672953
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mo1143 Is Lymph Node Ratio (LNR) a Prognostic Marker in Patients With Colon Cancer? A Study in National Cancer Institute's Surveillance Epidemiology, and End Results (SEER) Database

  2013cited by this paper
• Functional genomics identifies therapeutic targets for MYC-driven cancer

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

  2012cited by this paper
• BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia.

  2012cited by this paper
• Abstract P4-14-02: National Trends and Indications for Nipple-Sparing Mastectomy: An Analysis Using the Surveillance, Epidemiology, and End Results (SEER) Database

  2012cited by this paper
• Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family

  2012cited by this paper
• Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

  2012cited by this paper
• The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

  2012cited by this paper
• Systematic identification of genomic markers of drug sensitivity in cancer cells

  2012cited by this paper
• The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.

  2012cited by this paper
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

  2011cited by this paper
• Targeting MYC dependence in cancer by inhibiting BET bromodomains

  2011cited by this paper
• A decade of exploring the cancer epigenome — biological and translational implications

  2011cited by this paper
• Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia

  2011cited by this paper
• Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

  2011cited by this paper
• BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

  2011cited by this paper
• Molecular signatures database (MSigDB) 3.0

  2011cited by this paper
• Recent advances in neuroblastoma.

  2010cited by this paper
• Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification.

  2010cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• Inhibition of mutated, activated BRAF in metastatic melanoma.

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• PICNIC: an algorithm to predict absolute allelic copy number variation with microarray cancer data

  2009cited by this paper
• Brd4 marks select genes on mitotic chromatin and directs postmitotic transcription.

  2009cited by this paper
• Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

  2008cited by this paper
• Oncogenic mutations of ALK kinase in neuroblastoma

  2008cited by this paper
• Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

  2008cited by this paper
• Prevalence and functional consequence of PHOX2B mutations in neuroblastoma

  2008cited by this paper
• Identification of ALK as a major familial neuroblastoma predisposition gene

  2008cited by this paper
• Activating mutations in ALK provide a therapeutic target in neuroblastoma

  2008cited by this paper
• Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

  2007cited by this paper
• How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers

  2007cited by this paper
• GenePattern 2.0

  2006cited by this paper
• Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification

  2006cited by this paper
• From the Cover: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

  2005cited by this paper
• Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.

  2005cited by this paper
• The Phox2B homeobox gene is mutated in sporadic neuroblastomas

  2004cited by this paper
• Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma.

  2004cited by this paper
• Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia

  2004cited by this paper
• BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma.

  2003cited by this paper
• Bromodomain: an acetyl‐lysine binding domain

  2002cited by this paper
• Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  2001cited by this paper
• A LIM-homeodomain combinatorial code for motor-neuron pathway selection

  1999cited by this paper
• A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer.

  1998cited by this paper
• Targeted expression of MYCN causes neuroblastoma in transgenic mice

  1997cited by this paper
• An Information-Intensive Approach to the Molecular Pharmacology of Cancer

  1997cited by this paper
• Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas.

  1985cited by this paper
• Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

  1984cited by this paper
• Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour

  1983cited by this paper
• Activation of chromatin by acetylation of histone side chains.

  1976cited by this paper

• Dauricine induces ferroptosis in neuroblastoma by inhibiting methyltransferase-like 1-mediated N7-methylguanosine methylation of solute carrier family 3 member 2.

  2026cites this paper
• Prognostic value of vascular endothelial growth factor subtypes and risk models constructed based on the common pathway of ulcerative colitis and colon cancer

  2026cites this paper
• Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance

  2026cites this paper
• Switching off CK2-mediated activation of survivin offers new therapeutic opportunities in neuroblastoma

  2026cites this paper
• The protein phosphatase 2A-B56α complex regulates N-Myc degradation in neuroblastoma.

  2026cites this paper
• BRD4 Induces Esophageal Squamous Cell Carcinoma Progression via the Wnt/β-catenin Pathway

  2025cites this paper
• Overcoming BET‐inhibitor JQ1 resistance in aggressive non‐small cell lung cancer by inducing ferroptosis via inhibition of the BRD2–FTH1 axis

  2025cites this paper
• Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.

  2025cites this paper
• Molecular regulation and therapeutic targeting of MYCN in neuroblastoma: a comprehensive review

  2025cites this paper
• Recommended Tool Compounds: Thienotriazolodiazepines-Derivatized Chemical Probes to Target BET Bromodomains.

  2025cites this paper
• KAT6A/B inhibition synergizes with retinoic acid and enhances the efficacy of GD2-targeted immunotherapy in neuroblastoma

  2025cites this paper
• Final results from the phase Ia/Ib study of the novel bromodomain and extra-terminal domain inhibitor, BI 894999, in patients with advanced solid tumors or diffuse large B-cell lymphoma

  2025cites this paper
• Differentiation therapy targeting the stalled epigenetic developmental programs in pediatric high-grade gliomas.

  2025cites this paper
• Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities

  2025cites this paper
• Bromodomain containing protein 4 (BRD4) and cancer therapy: A glimpse at dual-target drug development.

  2025cites this paper
• Rhabdomyosarcoma: A Case Report and Comprehensive Literature Review

  2025cites this paper
• Advances of dual inhibitors based on ALK for the treatment of cancer.

  2025cites this paper
• High fructose promotes MYCN-amplified neuroblastoma progression through NgBR-ACSS2-mediated biosynthesis of acetyl-CoA.

  2025cites this paper
• Diminished MYCN Dosage Endows Cavitary Transformation in Retinoblastoma

  2025cites this paper
• Epigenetic Approaches to Prostate Cancer: Present Landscape and Future Prospects.

  2025cites this paper
• A Small Molecule Selectively Targets N-Myc to Suppress Neuroblastoma Cancer Progression

  2025cites this paper
• The chordoid glioma-associated PRKCA D463H mutation is a kinase inactive, gain-of-function allele that induces chondrosarcoma in mice

  2025cites this paper
• Interplay Between the Epigenome, the Microenvironment, and the Immune System in Neuroblastoma

  2025influential citation
• Case Report: Successful late-line pralsetinib treatment in an ALK-rearranged lung adenocarcinoma patient with KIF5B-RET fusion resistant to alectinib

  2025cites this paper
• The penetrant chordoid glioma PRKCA mutation is an oncogenic gain-of-function kinase inactivation eliciting early onset chondrosarcoma in mice

  2025cites this paper
• Chromatin Regulatory Targets for Anticancer Therapeutics.

  2025cites this paper
• m1A methylase TRMT6 promotes neuroblastoma development by demethylating SST mRNA in an m1A/YTHDF2-dependent manner

  2025cites this paper
• Cell-based assay to detect small molecules restoring levels of let-7 miRNAs.

  2024cites this paper
• Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma

  2024cites this paper
• The ROCK-1/2 inhibitor RKI-1447 blocks N-MYC, promotes cell death, and emerges as a synergistic partner for BET inhibitors in neuroblastoma.

  2024cites this paper
• Spliceosomal vulnerability of MYCN-amplified neuroblastoma is contingent on PRMT5-mediated regulation of epitranscriptomic and metabolomic pathways

  2024cites this paper
• The current status and future trends of BET research in oncology

  2024cites this paper
• Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma

  2024cites this paper
• Real-world performance of integrative clinical genomics in pediatric precision oncology.

  2024cites this paper
• An updated patent review of BRD4 degraders

  2024cites this paper
• Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity

  2024influential citation
• Pharmacological targeting of the cancer epigenome

  2024cites this paper
• Defining neuroblastoma: From origin to precision medicine

  2024cites this paper
• Unsaturated Fatty Acid Synthesis Is Associated with Worse Survival and Is Differentially Regulated by MYCN and Tumor Suppressor microRNAs in Neuroblastoma

  2024cites this paper
• Bromodomain inhibition targeting BPTF in the treatment of melanoma and other solid tumors

  2024cites this paper
• BET Bromodomain Inhibition Potentiates Ocular Melanoma Therapy by Inducing Cell Cycle Arrest

  2024cites this paper
• Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing associated with therapeutic response to splicing inhibitor

  2024influential citation
• KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m6A reader YTHDC1 protein degradation

  2024cites this paper
• Comparison of 177Lu-octreotate and 177Lu-octreotide for treatment in human neuroblastoma-bearing mice

  2024cites this paper
• Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity

  2024cites this paper
• A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway.

  2024cites this paper
• Established and Evolving Roles of the Multifunctional Non-POU Domain-Containing Octamer-Binding Protein (NonO) and Splicing Factor Proline- and Glutamine-Rich (SFPQ)

  2024cites this paper
• N-MYC regulates cell survival via eIF4G1 in inv(16) acute myeloid leukemia

  2024cites this paper
• MTHFD1 regulates the NADPH redox homeostasis in MYCN-amplified neuroblastoma

  2024cites this paper
• Therapeutic index of targeting select chromatin complexes in human cancer patients.

  2024cites this paper
• SESN1 functions as a new tumor suppressor gene via Toll‐like receptor signaling pathway in neuroblastoma

  2024cites this paper
• MYCN in neuroblastoma: the kings' new clothes and drugs

  2024cites this paper
• CAMKV Kinase Signaling Is a Novel Therapeutic Avenue with Prognostic Relevance in Neuroblastoma

  2024cites this paper
• Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor

  2023cites this paper
• Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma

  2023cites this paper
• IGF2BP1 induces neuroblastoma via a druggable feedforward loop with MYCN promoting 17q oncogene expression

  2023influential citation
• Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours.

  2023cites this paper
• A Comparative Study of Neuroendocrine Heterogeneity in Small Cell Lung Cancer and Neuroblastoma

  2023cites this paper
• Lipid Metabolic Reprogramming in Embryonal Neoplasms with MYCN Amplification

  2023cites this paper
• Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells

  2023cites this paper
• Bromo- and Extra-Terminal Domain Inhibitors Induce Mitochondrial Stress in Pancreatic Ductal Adenocarcinoma.

  2023cites this paper
• Modern treatment strategies in pediatric oncology and hematology

  2023cites this paper
• Role of non-coding RNAs in neuroblastoma

  2023cites this paper
• When Just One Phosphate Is One Too Many: The Multifaceted Interplay between Myc and Kinases

  2023cites this paper
• BET Bromodomain Degradation Disrupts Function but Not 3D Formation of RNA Pol2 Clusters

  2023cites this paper
• Targeting protein folding in N‐Myc‐driven medulloblastoma

  2023cites this paper
• N-MYC regulates Cell Survival via eIF4G1 in inv(16) Acute Myeloid Leukemia

  2023cites this paper
• Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme

  2023cites this paper
• Children's Oncology Group's 2023 blueprint for research: Neuroblastoma

  2023cites this paper
• Liquidhope: methylome and genomic profiling from very limited quantities of plasma-derived DNA

  2023cites this paper
• A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle

  2023cites this paper
• Chemical Inhibition of Bromodomain Proteins in Insect-Stage African Trypanosomes Perturbs Silencing of the Variant Surface Glycoprotein Repertoire and Results in Widespread Changes in the Transcriptome

  2023cites this paper
• IGF2BP1 induces high-risk neuroblastoma and forms a druggable feedforward loop with MYCN promoting 17q oncogene expression

  2023cites this paper
• HAND2 assists MYCN enhancer invasion to regulate a noradrenergic neuroblastoma phenotype.

  2023cites this paper
• Targeting the myeloid microenvironment in neuroblastoma

  2023cites this paper
• Precision Oncology in Pediatric Cancer Surgery.

  2023cites this paper
• Epigenetic Dysregulation in MYCN-Amplified Neuroblastoma

  2023cites this paper
• Subtype-selective prenylated isoflavonoids disrupt regulatory drivers of MYCN-amplified cancers.

  2023cites this paper
• Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy

  2023cites this paper
• Metabolic reprogramming of cancer cells by JMJD 6-mediated pre-mRNA splicing is associated 1 with therapeutic response to splicing inhibitor 2 3

  2023cites this paper
• RNA decay defines the response to transcriptional perturbation in leukaemia

  2023cites this paper
• Repurposing disulfiram, an alcohol-abuse drug, in neuroblastoma causes KAT2A downregulation and in vivo activity with a water/oil emulsion

  2023cites this paper
• Lenalidomide Derivative and PROTAC for Controlling Neosubstrate Degradation

  2023cites this paper
• Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative Breast Cancer.

  2023cites this paper
• Unraveling MYC’s Role in Orchestrating Tumor Intrinsic and Tumor Microenvironment Interactions Driving Tumorigenesis and Drug Resistance

  2023cites this paper
• Deficiency of BAP1 inhibits neuroblastoma tumorigenesis through destabilization of MYCN

  2023cites this paper
• Effect of CDK7 inhibitor on MYCN-amplified retinoblastoma.

  2023cites this paper
• Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation

  2023cites this paper
• New Approaches Towards Targeted Therapy for Childhood Neuroblastoma

  2023cites this paper
• A Novel Online Nomogram Established with Five Features before Surgical Resection for Predicating Prognosis of Neuroblastoma Children: A Population-Based Study

  2023influential citation
• Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?

  2023cites this paper
• A comparative study of neuroendocrine heterogeneity in SCLC and NBL

  2022cites this paper
• Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1

  2022cites this paper
• NONO enhances mRNA processing of super‐enhancer‐associated GATA2 and HAND2 genes in neuroblastoma

  2022cites this paper
• Overexpression of bromodomain and extraterminal domain is associated with progression, metastasis and unfavorable outcome: highlighting prognostic and therapeutic value of BET protein family in gastric cancer.

  2022cites this paper
• Combination bromo- and extraterminal domain and poly (ADP-ribose) polymerase inhibition synergistically enhances DNA damage and inhibits neuroblastoma tumorigenesis

  2022influential citation
• A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma

  2022influential citation
• Targeting BET proteins inhibited the growth of non‐small cell lung carcinoma through downregulation of Met expression

  2022cites this paper
• Targeting the Heterogeneous Genomic Landscape in Triple-Negative Breast Cancer through Inhibitors of the Transcriptional Machinery

  2022cites this paper
• MYCN Impact on High-Risk Neuroblastoma: From Diagnosis and Prognosis to Targeted Treatment

  2022cites this paper